Nektar Therapeutics (NKTR) Other Accumulated Expenses (2010 - 2026)

Nektar Therapeutics' Other Accumulated Expenses history runs 17 years deep, the most recent figure standing at $4.1 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses fell 65.67% year-over-year to $4.1 million; the TTM figure through Mar 2026 stood at $4.1 million (down 65.67% YoY), while the FY2025 annual figure was $2.7 million, down 72.59% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $4.1 million, up from $2.7 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $17.0 million in Q1 2022, with the low at $2.7 million in Q4 2025.
• The 5-year median for Other Accumulated Expenses is $8.3 million (2024), against an average of $9.2 million.
• The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses soared 185.8% in 2024, then slumped 72.59% in 2025.
• Nektar Therapeutics' Other Accumulated Expenses stood at $7.0 million in 2022, then slumped by 50.44% to $3.5 million in 2023, then jumped by 185.8% to $9.9 million in 2024, then plunged by 72.59% to $2.7 million in 2025, then jumped by 49.21% to $4.1 million in 2026.
• Business Quant data shows NKTR's Other Accumulated Expenses at $4.1 million in Q1 2026, $2.7 million in Q4 2025, and $12.1 million in Q3 2025.